Description
Toceranib is an inhibitor of receptor tyrosine kinases (RTKs).
Product Overview
Toceranib is an inhibitor which blocks various tyrosine kinases expressed on the cell surface. Receptor tyrosine kinases (RTKs) are excellent candidates for molecular targeted therapy, because they play key roles in controlling cell proliferation and survival and are frequently dysregulated in a variety of malignancies.
Synonyms
SU 11654; PHA 291639; SU11654; SU-11654; PHA-291639; PHA291639
Targets
KIT; VEGFR2; PDGFR2
Molecular Formula
C22H25FN4O2
Chemical Name
5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(2-pyrrolidin-1-ylethyl)-1H-pyrrole-3-carboxamide
Solubility
Limited solubility
Shipping Conditions
Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request
In vitro
Toceranib inhibited KIT phosphorylation and cell proliferation in a dose-dependent manner in the treatment-naïve, parental C2 line (IC50< 10 nM). In addition, chronic TOC exposure resulted in c-kit mRNA and KIT protein overexpression in the TOC-resistant sublines.
In vivo
Fourteen dogs with advanced mast cell tumors (MCTs) were enrolled in a prevoius study, among which 11 dogs were evaluable for KIT target modulation. Of these, eight MCTs showed reduced levels of phosphorylated KIT relative to total KIT after treatment with Toceranib, compared with pretreatment biopsies. All four evaluable MCTs expressing ITD mutant c-kit showed modulation of KIT phosphorylation, as did four of seven tumors expressing non-ITD c-kit.
Download Datasheet